Neuralstem in the News
U-M stem cell trial produces positive results for ALS patients
“The results suggest that [NSI-566] intraspinal stem cell transplantation of ALS subjects with no bulbar symptoms early in the course of their disease could slow disease progression,” Feldman said. “I am extremely hopeful that we have found a way early in the course of the disease to make a true difference. Any treatment that can slow the progression of the disease is truly a home run for Lou Gehrig.” ALS trial principal investigator, Dr. Eva Feldman, is quoted in this front-page feature story exploring Phase I results and the upcoming NSI-566/ALS Phase II trial planned this year, which will increase dosage and number of injections.
Human Stem Cells Help Acute SCI Rats; Chronic Trial Update
Neuralstem’s Chairman of the Board and Chief Scientific Officer, Karl Johe, Ph.D., shared insights on the breakthrough scientific research that led to the FDA approval of the upcoming NSI-566/chronic spinal cord injury trial with Christopher & Dana Reeve Foundation’s blogger, Sam Maddox. Mr. Maddox also identified the five planned trial centers.
FDA-approved Stem Cell Trial Dramatically Slows ALS
“Being a Michigan wolverine, I’ll use an analogy. It’s [no significant disease progression] as rare as a red wolf. And that is very rare,” says NSI-566/ALS clinical trial Principal Investigator Dr. Eva Feldman. Dr. Feldman and Neuralstem’s President and CEO Richard Garr are interviewed for this feature story that explores the new ALS Phase I data from six of the extraordinary responders, after Dr. Feldman presented it at the Romanian Neurological Society Congress earlier in May.
Neuralstem Sees Breakthrough In Spinal Cord Injury
Neuralstem’s FDA-approved NSI-566/chronic spinal cord injury clinical trial, expected to commence in the second half of 2013, is explored and its four U.S. centers named, in this expansive article. It includes reference to the company’s planned 2013 acute SCI trial in South Korea, and cites promising preclinical SCI animal data published recently in Stem Cell Research & Therapy, and additional SCI data published by science journal, Cell, last year.
Doctor Radio Feature Interview with Dr. Feldman and Ted Harada
Doctor Radio host, NYU’s Dr. Nieca Goldberg, interviews NSI-566/ALS principal investigator Dr. Eva Feldman and Phase I patient Ted Harada in this expansive one-hour segment on ALS that brought calls from present and past ALS caregivers from around the country. The feature includes firsthand insights on Neuralstem’s completed and upcoming ALS trials. Notably Dr. Feldman said that, while the trial is just entering Phase II, that the team believes the results are extremely promising, and pointed out the heretofore dearth of ALS treatments for this chronic, progressive, neurodegenerative disease since Lou Gehrig was diagnosed in the 1930’s. Ted shared poignant and heartfelt “new lease on life” memories after his initial NSI-566 treatment - and a call to action as well as support for the ALS community from his spot on Capitol Hill, where he was meeting with senators and representatives on National ALS Advocacy Day.
Podcast on demand available to SiriusXM Subscribers: Doctor Radio, Women's Health, 5/9/13 10:00-11:00 a.m. ET
5/12 and 5/13 Rebroadcast: Women's Health: Sun, 5/12, 2:00 a.m. ET (Sat., 5/11, 11:00 p.m. PT) and Mon, 5/13, 4:00 a.m. ET
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.